Literature DB >> 24327743

Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis.

Shinichi Arizono1, Hiroyuki Taniguchi2, Koji Sakamoto3, Yasuhiro Kondoh4, Tomoki Kimura4, Kensuke Kataoka4, Tomoya Ogawa5, Fumiko Watanabe5, Osamu Nishiyama6, Koichi Nishimura7, Ryo Kozu8, Kazuyuki Tabira9.   

Abstract

BACKGROUND: Although pulmonary rehabilitation (PR) has been reported to improve exercise capacity in patients with idiopathic pulmonary fibrosis, it is unknown which exercise measurement is the most responsive for evaluation of PR efficacy. The purpose of this study was to compare the responsiveness of 5 exercise measurements by evaluating the efficacy of PR in subjects with idiopathic pulmonary fibrosis.
METHODS: We conducted a prospective observational study in which 53 subjects with idiopathic pulmonary fibrosis were enrolled. The PR group underwent a 10-week out-patient PR program. The control group was observed without any additional intervention, including PR. Five exercise measurements (endurance time [ET], peak work rate, peak oxygen consumption [V̇O2 ], 6-min walk distance, and incremental shuttle walk distance) were evaluated at baseline and after 10 weeks. The effect size was used for the assessment of responsiveness.
RESULTS: In each group, 24 subjects completed the 5 measurements at baseline and after 10 weeks. The changes in ET (PR: 181.6%; control: -8.2%), peak V̇O2 (PR: 7.6%; control: -5.4%), peak work rate (PR: 15.1%; control: -5.1%), 6-min walk distance (PR: 6.0%; control: -3.8%), and incremental shuttle walk distance (PR: 9.1%; control: -5.1%) were significantly different between the groups after 10 weeks (P < .05). In the PR group, ET showed the most striking improvement among the 5 measurements (P < .05), and its effect size was as large as 2.96, whereas those of the others were all < 0.5.
CONCLUSIONS: ET is the most responsive exercise measurement for evaluating PR efficacy in patients with idiopathic pulmonary fibrosis.
Copyright © 2014 by Daedalus Enterprises.

Entities:  

Keywords:  endurance time; exercise capacity; idiopathic pulmonary fibrosis; pulmonary rehabilitation; responsiveness

Mesh:

Year:  2013        PMID: 24327743     DOI: 10.4187/respcare.02674

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  14 in total

1.  Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison with chronic obstructive pulmonary disease.

Authors:  Shinichi Arizono; Hiroyuki Taniguchi; Koji Sakamoto; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Kazuyuki Tabira; Ryo Kozu
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Current best practice in rehabilitation in interstitial lung disease.

Authors:  Atsuhito Nakazawa; Narelle S Cox; Anne E Holland
Journal:  Ther Adv Respir Dis       Date:  2016-11-15       Impact factor: 4.031

Review 3.  Pulmonary rehabilitation for interstitial lung disease.

Authors:  Leona Dowman; Catherine J Hill; Anthony May; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2021-02-01

4.  Effects of different exercise training programs on the functional performance in fibrosing interstitial lung diseases: A randomized trial.

Authors:  Hatem Essam; Nashwa Hassan Abdel Wahab; Gihan Younis; Enas El-Sayed; Hanaa Shafiek
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

5.  Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Kensuke Kataoka; Masahiko Ando; Shinichi Arizono; Akira Morino; Koichi Nishimura; Tomoya Ogawa; Akira Shiraki; Fumiko Watanabe; Ryo Kozu; Takashi Ogura; Yasuhiro Kondoh
Journal:  ERJ Open Res       Date:  2021-08-23

Review 6.  Exercise training in idiopathic pulmonary fibrosis: is it of benefit?

Authors:  Baruch Vainshelboim
Journal:  Breathe (Sheff)       Date:  2016-06

7.  Marathon Race Affects Neutrophil Surface Molecules: Role of Inflammatory Mediators.

Authors:  Vinicius Coneglian Santos; Ana Paula Renno Sierra; Rodrigo Oliveira; Kim Guimarães Caçula; César Miguel Momesso; Fabio Takeo Sato; Maysa Braga Barros Silva; Heloisa Helena Oliveira; Maria Elizabeth Pereira Passos; Diego Ribeiro de Souza; Olivia Santos Gondim; Marino Benetti; Adriana Cristina Levada-Pires; Nabil Ghorayeb; Maria Augusta Peduti Dal Molin Kiss; Renata Gorjão; Tânia Cristina Pithon-Curi; Maria Fernanda Cury-Boaventura
Journal:  PLoS One       Date:  2016-12-02       Impact factor: 3.240

8.  Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial.

Authors:  Inga Jarosch; Tessa Schneeberger; Rainer Gloeckl; Michael Kreuter; Marion Frankenberger; Claus Neurohr; Antje Prasse; Julia Freise; Juergen Behr; Wolfgang Hitzl; Andreas R Koczulla; Klaus Kenn
Journal:  J Clin Med       Date:  2020-05-21       Impact factor: 4.241

Review 9.  Update on therapeutic management of idiopathic pulmonary fibrosis.

Authors:  Argyris Tzouvelekis; Francesco Bonella; Paolo Spagnolo
Journal:  Ther Clin Risk Manag       Date:  2015-03-03       Impact factor: 2.423

10.  Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial.

Authors:  Narelle S Cox; Christine F McDonald; Jennifer A Alison; Ajay Mahal; Richard Wootton; Catherine J Hill; Janet Bondarenko; Heather Macdonald; Paul O'Halloran; Paolo Zanaboni; Ken Clarke; Deidre Rennick; Kaye Borgelt; Angela T Burge; Aroub Lahham; Bruna Wageck; Hayley Crute; Pawel Czupryn; Amanda Nichols; Anne E Holland
Journal:  BMC Pulm Med       Date:  2018-05-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.